You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEpoprostenol
Accession NumberDB01240  (APRD00949)
TypeSmall Molecule
GroupsApproved
DescriptionA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Structure
Thumb
Synonyms
(5Z,13e)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,9alpha,11alpha,13e,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostenol
Flolan
PGI2
PGX
Prostacyclin
Prostaglandin I2
Prostaglandin x
Vasocyclin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CaripulPowder, for solution0.5 mgIntravenousActelion Pharmaceuticals Ltd2013-04-24Not applicableCanada
CaripulPowder, for solution1.5 mgIntravenousActelion Pharmaceuticals Ltd2013-04-24Not applicableCanada
Epoprostenol for InjectionPowder, for solution1.5 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Epoprostenol for InjectionPowder, for solution0.5 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
FlolanPowder, for solution1.5 mgIntravenousGlaxosmithkline Inc1997-07-28Not applicableCanada
FlolanInjection, powder, lyophilized, for solution.5 mg/1IntravenousGlaxo Smith Kline Llc1995-12-08Not applicableUs
FlolanInjection, powder, lyophilized, for solution1.5 mg/1IntravenousGlaxo Smith Kline Llc1995-12-08Not applicableUs
FlolanPowder, for solution0.5 mgIntravenousGlaxosmithkline Inc1997-07-28Not applicableCanada
VeletriInjection, powder, lyophilized, for solution1500000 ng/10mLIntravenousActelion Pharmaceuticals US, Inc.2010-04-22Not applicableUs
VeletriInjection, powder, lyophilized, for solution1500000 ng/10mLIntravenousActelion Pharmaceuticals US, Inc.2010-04-22Not applicableUs
VeletriInjection, powder, lyophilized, for solution500000 ng/10mLIntravenousActelion Pharmaceuticals US, Inc.2010-04-22Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Epoprostenol SodiumInjection, powder, for solution.5 mg/1IntravenousTeva Parenteral Medicines, Inc.2008-04-23Not applicableUs
Epoprostenol SodiumInjection, powder, for solution1.5 mg/1IntravenousTeva Parenteral Medicines, Inc.2008-04-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Epoprostenol sodium
ThumbNot applicableDBSALT001218
Categories
UNIIDCR9Z582X0
CAS number35121-78-9
WeightAverage: 352.4651
Monoisotopic: 352.224974134
Chemical FormulaC20H32O5
InChI KeyKAQKFAOMNZTLHT-OZUDYXHBSA-N
InChI
InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1
IUPAC Name
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-2-ylidene]pentanoic acid
SMILES
[H][C@]12C[C@@H](O)[[email protected]](\C=C\[C@@H](O)CCCCC)[C@@]1([H])CC(O2)=CCCCC(O)=O
Pharmacology
IndicationFor the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Structured Indications
PharmacodynamicsEpoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.
Mechanism of actionProstaglandins are present in most body tissues and fluids and mediate many biological functions. Epoprostenol (PGI2) is a member of the family of prostaglandins that is derived from arachidonic acid. The major pharmacological actions of epoprostenol is ultimately inhibition of platelet aggregation. Prostacyclin (PGI2) is released by healthy endothelial cells and performs its function through a paracrine signaling cascade that involves G protein-coupled receptors on nearby platelets and endothelial cells. The platelet Gs protein-coupled receptor (prostacyclin receptor) is activated when it binds to PGI2. This activation, in turn, signals adenylyl cyclase to produce cAMP. cAMP goes on to inhibit any undue platelet activation (in order to promote circulation) and also counteracts any increase in cytosolic calcium levels which would result from thromboxane A2 (TXA2) binding (leading to platelet activation and subsequent coagulation). PGI2 also binds to endothelial prostacyclin receptors and in the same manner raise cAMP levels in the cytosol. This cAMP then goes on to activate protein kinase A (PKA). PKA then continues the cascade by phosphorylating and inhibiting myosin light-chain kinase which leads to smooth muscle relaxation and vasodilation. Notably, PGI2 and TXA2 work as physiological antagonists.
TargetKindPharmacological actionActionsOrganismUniProt ID
P2Y purinoceptor 12Proteinyes
agonist
HumanQ9H244 details
Prostacyclin receptorProteinyes
agonist
HumanP43119 details
Prostacyclin synthaseProteinyes
inducer
HumanQ16647 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 357 mL/kg
Protein bindingNot Available
Metabolism

Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.

SubstrateEnzymesProduct
Epoprostenol
Not Available
6,15-Diketo-13,14-dihydro-PGF1-alphaDetails
Epoprostenol
Not Available
6-Keto-PGF1-alphaDetails
Route of eliminationEpoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.
Half lifeThe in vitro half-life of epoprostenol in human blood at 37°C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.
ClearanceNot Available
ToxicitySymptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Epoprostenol.Experimental
AbciximabEpoprostenol may increase the antiplatelet activities of Abciximab.Approved
AbirateroneThe metabolism of Epoprostenol can be decreased when combined with Abiraterone.Approved
AcebutololAcebutolol may increase the hypotensive activities of Epoprostenol.Approved
AceclofenacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Aceclofenac.Approved
AcenocoumarolEpoprostenol may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Epoprostenol.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Epoprostenol.Approved, Investigational
AliskirenEpoprostenol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Epoprostenol.Approved, Withdrawn
AlprostadilEpoprostenol may increase the antiplatelet activities of Alprostadil.Approved, Investigational
AlteplaseEpoprostenol may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Epoprostenol may increase the anticoagulant activities of ALX-0081.Investigational
AmbrisentanEpoprostenol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineEpoprostenol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Epoprostenol.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Epoprostenol can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Epoprostenol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Epoprostenol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Epoprostenol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Epoprostenol.Approved
AnagrelideEpoprostenol may increase the antiplatelet activities of Anagrelide.Approved
AncrodEpoprostenol may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Anisodamine.Investigational
AnistreplaseEpoprostenol may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Antipyrine.Approved
Antithrombin III humanEpoprostenol may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Apixaban.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Epoprostenol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Epoprostenol.Approved
ApremilastThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Apremilast.Approved, Investigational
AprepitantThe metabolism of Epoprostenol can be increased when combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinEpoprostenol may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanEpoprostenol may increase the antiplatelet activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Epoprostenol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Epoprostenol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Epoprostenol.Approved, Investigational
AstaxanthinEpoprostenol may increase the anticoagulant activities of Astaxanthin.Investigational
AtenololAtenolol may increase the hypotensive activities of Epoprostenol.Approved
AzapropazoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineEpoprostenol may increase the antiplatelet activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Epoprostenol.Approved
BalsalazideThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Epoprostenol.Experimental
BarbitalBarbital may increase the hypotensive activities of Epoprostenol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Epoprostenol.Approved
BatroxobinEpoprostenol may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminEpoprostenol may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinEpoprostenol may increase the anticoagulant activities of Bemiparin.Approved
BenazeprilBenazepril may increase the hypotensive activities of Epoprostenol.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Epoprostenol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Epoprostenol.Withdrawn
BenoxaprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Benoxaprofen.Withdrawn
BepridilEpoprostenol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostEpoprostenol may increase the antiplatelet activities of Beraprost.Investigational
BetaxololBetaxolol may increase the hypotensive activities of Epoprostenol.Approved
BethanidineBethanidine may increase the hypotensive activities of Epoprostenol.Approved
Betulinic AcidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Betulinic Acid.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Epoprostenol.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Epoprostenol.Approved
BivalirudinEpoprostenol may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Epoprostenol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Epoprostenol.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Epoprostenol.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Epoprostenol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Epoprostenol.Approved
BromfenacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Epoprostenol.Approved, Investigational
BucillamineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Epoprostenol.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Epoprostenol.Approved, Investigational
BupranololEpoprostenol may increase the hypotensive activities of Bupranolol.Approved
ButylphthalideEpoprostenol may increase the antiplatelet activities of Butylphthalide.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Epoprostenol.Approved
CandesartanCandesartan may increase the hypotensive activities of Epoprostenol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Epoprostenol.Experimental
CangrelorEpoprostenol may increase the antiplatelet activities of Cangrelor.Approved
CapecitabineThe metabolism of Epoprostenol can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilCaptopril may increase the hypotensive activities of Epoprostenol.Approved
CarbamazepineThe metabolism of Epoprostenol can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Epoprostenol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Epoprostenol.Withdrawn
CarprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Epoprostenol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Epoprostenol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololEpoprostenol may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Epoprostenol can be increased when it is combined with Ceritinib.Approved
CertoparinEpoprostenol may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Epoprostenol.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Epoprostenol.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Epoprostenol.Approved
CholecalciferolThe metabolism of Epoprostenol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilEpoprostenol may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Epoprostenol.Approved
CilostazolEpoprostenol may increase the antiplatelet activities of Cilostazol.Approved
Citric AcidEpoprostenol may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Epoprostenol.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Epoprostenol.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Epoprostenol.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Epoprostenol.Approved
ClonixinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Clonixin.Approved
ClopidogrelEpoprostenol may increase the antiplatelet activities of Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Epoprostenol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Epoprostenol.Approved
CollagenaseThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Collagenase.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Epoprostenol.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Epoprostenol.Approved
CurcuminThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Curcumin.Investigational
CyclosporineThe metabolism of Epoprostenol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Epoprostenol.Approved
D-LimoneneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with D-Limonene.Investigational
Dabigatran etexilateEpoprostenol may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Epoprostenol can be decreased when it is combined with Dabrafenib.Approved
DalteparinEpoprostenol may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEpoprostenol may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Epoprostenol.Approved
DasatinibDasatinib may increase the anticoagulant activities of Epoprostenol.Approved, Investigational
DebrisoquinEpoprostenol may increase the hypotensive activities of Debrisoquin.Approved
DefibrotideEpoprostenol may increase the antiplatelet activities of Defibrotide.Approved, Investigational
DelavirdineThe metabolism of Epoprostenol can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Epoprostenol is combined with dersalazine.Investigational
DeserpidineEpoprostenol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Epoprostenol.Approved
DesirudinEpoprostenol may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseEpoprostenol may increase the anticoagulant activities of Desmoteplase.Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Epoprostenol.Approved, Vet Approved
DextranEpoprostenol may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Epoprostenol may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Epoprostenol may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Epoprostenol may increase the anticoagulant activities of Dextran 75.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Epoprostenol.Approved
DiclofenacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Epoprostenol.Approved
DicoumarolEpoprostenol may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Diflunisal.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Epoprostenol.Approved
DihydralazineEpoprostenol may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Epoprostenol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Epoprostenol.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Epoprostenol.Approved
DitazoleEpoprostenol may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DorzolamideDorzolamide may increase the hypotensive activities of Epoprostenol.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Epoprostenol.Approved
Drotrecogin alfaEpoprostenol may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Droxicam.Approved
DuloxetineEpoprostenol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Epoprostenol can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ebselen.Investigational
Edetic AcidEpoprostenol may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEpoprostenol may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Epoprostenol can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineEpoprostenol may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Epoprostenol.Approved
EnalaprilEnalapril may increase the hypotensive activities of Epoprostenol.Approved, Vet Approved
EnalaprilatEpoprostenol may increase the hypotensive activities of Enalaprilat.Approved
EnoxaparinEpoprostenol may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpoprostenol may increase the antiplatelet activities of Epinastine.Approved, Investigational
EpirizoleThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Epoprostenol.Approved
eplivanserineEpoprostenol may increase the antiplatelet activities of eplivanserine.Investigational
EprosartanEprosartan may increase the hypotensive activities of Epoprostenol.Approved
EptifibatideEpoprostenol may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Epoprostenol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Epoprostenol.Approved
EtanerceptThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etanercept.Approved, Investigational
Ethyl biscoumacetateEpoprostenol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etofenamate.Approved
EtoricoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Epoprostenol can be decreased when combined with Etravirine.Approved
Evening primrose oilThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Evening primrose oil.Approved
exisulindThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with exisulind.Investigational
FelodipineFelodipine may increase the hypotensive activities of Epoprostenol.Approved, Investigational
FenbufenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Epoprostenol.Approved
FenoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenoprofen.Approved
FibrinolysinEpoprostenol may increase the anticoagulant activities of Fibrinolysin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Fimasartan.Approved
FloctafenineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Epoprostenol can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Epoprostenol can be decreased when combined with Fluconazole.Approved
FluindioneEpoprostenol may increase the anticoagulant activities of Fluindione.Investigational
FlunixinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Flunixin.Vet Approved
FluorouracilThe metabolism of Epoprostenol can be decreased when combined with Fluorouracil.Approved
FlurbiprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvastatinThe metabolism of Epoprostenol can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Epoprostenol can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxEpoprostenol may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEpoprostenol may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Epoprostenol.Approved
FosphenytoinThe metabolism of Epoprostenol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Epoprostenol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Epoprostenol.Approved, Vet Approved
GabexateEpoprostenol may increase the anticoagulant activities of Gabexate.Investigational
GemfibrozilThe metabolism of Epoprostenol can be decreased when combined with Gemfibrozil.Approved
GlucosamineGlucosamine may increase the antiplatelet activities of Epoprostenol.Approved
GuanabenzGuanabenz may increase the hypotensive activities of Epoprostenol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Epoprostenol.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Epoprostenol.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Epoprostenol.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Halothane.Approved, Vet Approved
HeparinEpoprostenol may increase the anticoagulant activities of Heparin.Approved, Investigational
HexamethoniumEpoprostenol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Epoprostenol.Approved
HigenamineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Higenamine.Investigational
HirulogEpoprostenol may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The therapeutic efficacy of Epoprostenol can be decreased when used in combination with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Epoprostenol.Approved
HydralazineEpoprostenol may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Epoprostenol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Epoprostenol.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Epoprostenol.Approved
IbudilastEpoprostenol may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Icatibant.Approved
Icosapent ethylEpoprostenol may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
idraparinuxEpoprostenol may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilEpoprostenol may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloprostThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Imipramine.Approved
IndapamideIndapamide may increase the hypotensive activities of Epoprostenol.Approved
IndenololEpoprostenol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Epoprostenol can be decreased when combined with Indinavir.Approved
IndobufenEpoprostenol may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminEpoprostenol may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Epoprostenol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Epoprostenol.Withdrawn
IrbesartanThe metabolism of Epoprostenol can be decreased when combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Epoprostenol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Epoprostenol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Epoprostenol.Approved
IsoxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Epoprostenol.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Epoprostenol.Approved
Kct 0809Epoprostenol may increase the anticoagulant activities of Kct 0809.Investigational
KebuzoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Kebuzone.Experimental
KetanserinEpoprostenol may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Epoprostenol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Epoprostenol.Approved
LacidipineEpoprostenol may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Epoprostenol.Approved, Investigational
LeflunomideThe metabolism of Epoprostenol can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinEpoprostenol may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Epoprostenol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Epoprostenol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Levobupivacaine.Approved
LevodopaEpoprostenol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Levosimendan.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Epoprostenol.Approved
LisinoprilLisinopril may increase the hypotensive activities of Epoprostenol.Approved, Investigational
LisofyllineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lisofylline.Investigational
LofexidineEpoprostenol may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lornoxicam.Approved
LosartanThe metabolism of Epoprostenol can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Epoprostenol can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Loxoprofen.Approved
LumacaftorThe serum concentration of Epoprostenol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanEpoprostenol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineEpoprostenol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Epoprostenol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Epoprostenol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Epoprostenol.Approved
Meclofenamic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Metamizole.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Epoprostenol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Epoprostenol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Epoprostenol.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Epoprostenol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Epoprostenol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Epoprostenol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Epoprostenol.Approved
MetipranololMetipranolol may increase the hypotensive activities of Epoprostenol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Epoprostenol.Approved
MetoprololMetoprolol may increase the hypotensive activities of Epoprostenol.Approved, Investigational
MetyrosineEpoprostenol may increase the hypotensive activities of Metyrosine.Approved
MibefradilEpoprostenol may increase the hypotensive activities of Mibefradil.Withdrawn
MifepristoneThe serum concentration of Epoprostenol can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneEpoprostenol may increase the antiplatelet activities of Milrinone.Approved
MinaprineMinaprine may increase the hypotensive activities of Epoprostenol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Epoprostenol.Approved
MizoribineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Epoprostenol.Approved
MoexiprilMoexipril may increase the hypotensive activities of Epoprostenol.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Epoprostenol.Approved
MorphineThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Morphine.Approved, Investigational
MoxonidineEpoprostenol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Epoprostenol.Approved
NadroparinEpoprostenol may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Naftifine.Approved
NaftopidilEpoprostenol may increase the antiplatelet activities of Naftopidil.Investigational
NaproxenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Epoprostenol is combined with NCX 4016.Investigational
NebivololEpoprostenol may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Epoprostenol.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Epoprostenol.Withdrawn
NicardipineThe metabolism of Epoprostenol can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Epoprostenol.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Epoprostenol.Approved
Niflumic AcidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineEpoprostenol may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineEpoprostenol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideEpoprostenol may increase the antiplatelet activities of Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Epoprostenol.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Epoprostenol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Epoprostenol.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Epoprostenol.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Epoprostenol.Approved
ObinutuzumabEpoprostenol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Epoprostenol.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Epoprostenol.Approved, Investigational
OlopatadineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Epoprostenol.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Epoprostenol.Approved
OmeprazoleThe metabolism of Epoprostenol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Orgotein.Vet Approved
OtamixabanEpoprostenol may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxaprozin.Approved
OxprenololEpoprostenol may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Epoprostenol.Approved
ParecoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Epoprostenol.Approved
ParnaparinEpoprostenol may increase the anticoagulant activities of Parnaparin.Approved
PenbutololEpoprostenol may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Epoprostenol.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Epoprostenol.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epoprostenol.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Epoprostenol.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Epoprostenol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Epoprostenol.Approved
PhenindioneEpoprostenol may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Epoprostenol.Withdrawn
PhenobarbitalThe metabolism of Epoprostenol can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Epoprostenol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Epoprostenol.Withdrawn
PhenprocoumonEpoprostenol may increase the anticoagulant activities of Phenprocoumon.Approved
PhentolaminePhentolamine may increase the hypotensive activities of Epoprostenol.Approved
PhenylbutazoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Epoprostenol can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilEpoprostenol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPindolol may increase the hypotensive activities of Epoprostenol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Pipamperone.Approved
PirfenidoneThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Epoprostenol.Approved
PiroxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Epoprostenol.Withdrawn
PlasminEpoprostenol may increase the anticoagulant activities of Plasmin.Investigational
PolythiazideEpoprostenol may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Pramipexole.Approved, Investigational
PrasugrelEpoprostenol may increase the antiplatelet activities of Prasugrel.Approved
PrazosinPrazosin may increase the hypotensive activities of Epoprostenol.Approved
PrimidoneThe metabolism of Epoprostenol can be increased when combined with Primidone.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Epoprostenol.Approved, Investigational
Protein CEpoprostenol may increase the anticoagulant activities of Protein C.Approved
Protein S humanEpoprostenol may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEpoprostenol may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299The therapeutic efficacy of Epoprostenol can be decreased when used in combination with PTC299.Investigational
PyrimethamineThe metabolism of Epoprostenol can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Epoprostenol.Approved
QuinaprilQuinapril may increase the hypotensive activities of Epoprostenol.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Epoprostenol.Approved
RamatrobanEpoprostenol may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilRamipril may increase the hypotensive activities of Epoprostenol.Approved
RasagilineRasagiline may increase the hypotensive activities of Epoprostenol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Epoprostenol.Approved
RescinnamineEpoprostenol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Epoprostenol.Approved
ResveratrolEpoprostenol may increase the antiplatelet activities of Resveratrol.Experimental, Investigational
ReteplaseEpoprostenol may increase the anticoagulant activities of Reteplase.Approved
ReviparinEpoprostenol may increase the anticoagulant activities of Reviparin.Approved
RidogrelEpoprostenol may increase the antiplatelet activities of Ridogrel.Approved
RifampicinThe metabolism of Epoprostenol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Epoprostenol can be increased when combined with Rifapentine.Approved
RilmenidineEpoprostenol may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatEpoprostenol may increase the hypotensive activities of Riociguat.Approved
RisperidoneEpoprostenol may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabEpoprostenol may increase the hypotensive activities of Rituximab.Approved
RivaroxabanEpoprostenol may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Ropivacaine.Approved
RosiglitazoneEpoprostenol may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Epoprostenol.Withdrawn
SalicylamideThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salsalate.Approved
SaprisartanEpoprostenol may increase the hypotensive activities of Saprisartan.Experimental
SCH-530348Epoprostenol may increase the antiplatelet activities of SCH-530348.Investigational
SecobarbitalThe metabolism of Epoprostenol can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Epoprostenol.Approved, Investigational, Vet Approved
SelexipagEpoprostenol may increase the anticoagulant activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Epoprostenol.Approved, Investigational
SitaxentanEpoprostenol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Sodium Nitrite.Approved
SorafenibThe metabolism of Epoprostenol can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Epoprostenol.Approved
SpiraprilEpoprostenol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Epoprostenol.Approved
SRT501Epoprostenol may increase the antiplatelet activities of SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Epoprostenol can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Epoprostenol can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Epoprostenol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulindac.Approved
SulodexideEpoprostenol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Epoprostenol.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tamsulosin.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Epoprostenol.Approved, Investigational
TemocaprilEpoprostenol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenecteplaseEpoprostenol may increase the anticoagulant activities of Tenecteplase.Approved
TenoxicamThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Epoprostenol.Approved
TeriflunomideThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Teriflunomide.Approved
TerlipressinEpoprostenol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneEpoprostenol may increase the antiplatelet activities of Tesmilifene.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Epoprostenol.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Epoprostenol.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Thioridazine.Approved
Tiaprofenic acidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneEpoprostenol may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe metabolism of Epoprostenol can be decreased when combined with Ticagrelor.Approved
TiclopidineEpoprostenol may increase the antiplatelet activities of Ticlopidine.Approved
TicrynafenEpoprostenol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Epoprostenol.Approved
TinoridineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tinoridine.Investigational
TinzaparinEpoprostenol may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Epoprostenol.Approved, Investigational
TirofibanEpoprostenol may increase the antiplatelet activities of Tirofiban.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Epoprostenol.Approved
TolazolineTolazoline may increase the hypotensive activities of Epoprostenol.Approved, Vet Approved
TolbutamideThe metabolism of Epoprostenol can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Epoprostenol.Approved
TorasemideTorasemide may increase the hypotensive activities of Epoprostenol.Approved
TositumomabThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tositumomab.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Epoprostenol.Approved
TranilastEpoprostenol may increase the antiplatelet activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Epoprostenol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Epoprostenol.Approved
TrapidilEpoprostenol may increase the antiplatelet activities of Trapidil.Approved
TravoprostTravoprost may increase the hypotensive activities of Epoprostenol.Approved
TreprostinilTreprostinil may increase the antiplatelet activities of Epoprostenol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Epoprostenol.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Epoprostenol.Approved, Vet Approved
TriflusalEpoprostenol may increase the antiplatelet activities of Triflusal.Approved
TrimazosinEpoprostenol may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Epoprostenol.Approved
TrimethoprimThe metabolism of Epoprostenol can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Epoprostenol.Approved, Investigational
UnoprostoneEpoprostenol may increase the hypotensive activities of Unoprostone.Approved
UrokinaseEpoprostenol may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Epoprostenol can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Epoprostenol can be decreased when combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Epoprostenol.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Epoprostenol.Approved
VinpocetineEpoprostenol may increase the hypotensive activities of Vinpocetine.Investigational
Vitamin EVitamin E may increase the antiplatelet activities of Epoprostenol.Approved, Nutraceutical, Vet Approved
VorapaxarEpoprostenol may increase the antiplatelet activities of Vorapaxar.Approved
VoriconazoleThe metabolism of Epoprostenol can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEpoprostenol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEpoprostenol may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineEpoprostenol may increase the hypotensive activities of Xylometazoline.Approved
Ym150Epoprostenol may increase the anticoagulant activities of Ym150.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Epoprostenol.Approved, Vet Approved
ZafirlukastThe metabolism of Epoprostenol can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Nagesh R. Palepu, “NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF.” U.S. Patent US20090088468, issued April 02, 2009.

US20090088468
General ReferencesNot Available
External Links
ATC CodesB01AC09
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (1.28 MB)
MSDSDownload (40.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9922
Blood Brain Barrier+0.8767
Caco-2 permeable+0.5636
P-glycoprotein substrateSubstrate0.6946
P-glycoprotein inhibitor INon-inhibitor0.9131
P-glycoprotein inhibitor IINon-inhibitor0.8879
Renal organic cation transporterNon-inhibitor0.8878
CYP450 2C9 substrateNon-substrate0.8171
CYP450 2D6 substrateNon-substrate0.8622
CYP450 3A4 substrateSubstrate0.5384
CYP450 1A2 substrateNon-inhibitor0.5729
CYP450 2C9 inhibitorNon-inhibitor0.9251
CYP450 2D6 inhibitorNon-inhibitor0.9401
CYP450 2C19 inhibitorNon-inhibitor0.75
CYP450 3A4 inhibitorNon-inhibitor0.6126
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8673
Ames testNon AMES toxic0.7865
CarcinogenicityNon-carcinogens0.9555
BiodegradationNot ready biodegradable0.5964
Rat acute toxicity2.6928 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8304
hERG inhibition (predictor II)Non-inhibitor0.8759
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous.5 mg/1
Injection, powder, for solutionIntravenous1.5 mg/1
Injection, powder, lyophilized, for solutionIntravenous.5 mg/1
Injection, powder, lyophilized, for solutionIntravenous1.5 mg/1
Powder, for solutionIntravenous0.5 mg
Powder, for solutionIntravenous1.5 mg
Injection, powder, lyophilized, for solutionIntravenous1500000 ng/10mL
Injection, powder, lyophilized, for solutionIntravenous500000 ng/10mL
Prices
Unit descriptionCostUnit
Flolan 1.5 mg vial51.59USD vial
Epoprostenol sodium 1.5 mg vial33.53USD vial
Flolan 0.5 mg vial21.36USD vial
Epoprostenol sodium 0.5 mg vial13.88USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8318802 No2007-03-152027-03-15Us
US8598227 No2007-02-022027-02-02Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.136 mg/mLALOGPS
logP3.83ALOGPS
logP2.42ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.43ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity99.01 m3·mol-1ChemAxon
Polarizability41.62 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Medium-chain hydroxy acid
  • Fatty alcohol
  • Medium-chain fatty acid
  • Heterocyclic fatty acid
  • Oxolane
  • Cyclic alcohol
  • Secondary alcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name:
P2RY12
Uniprot ID:
Q9H244
Molecular Weight:
39438.355 Da
References
  1. Cattaneo M, Lecchi A: Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost. 2007 Mar;5(3):577-82. Epub 2006 Dec 7. [PubMed:17155953 ]
  2. Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, Woulfe D, Brass LF: Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem. 2002 Nov 29;277(48):46035-42. Epub 2002 Sep 23. [PubMed:12297509 ]
  3. Kobsar AL, Koessler J, Rajkovic MS, Brunner KP, Steigerwald U, Walter U: Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system. Platelets. 2010;21(2):112-6. doi: 10.3109/09537100903440937. [PubMed:20085435 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name:
PTGIR
Uniprot ID:
P43119
Molecular Weight:
40955.485 Da
References
  1. Kasza Z, Fetalvero KM, Ding M, Wagner RJ, Acs K, Guzman AK, Douville KL, Powell RJ, Hwa J, Martin KA: Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94. doi: 10.1016/j.yjmcc.2009.01.006. Epub 2009 Jan 23. [PubMed:19302827 ]
  2. Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, Woulfe D, Brass LF: Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem. 2002 Nov 29;277(48):46035-42. Epub 2002 Sep 23. [PubMed:12297509 ]
  3. Ibrahim S, Tetruashvily M, Frey AJ, Wilson SJ, Stitham J, Hwa J, Smyth EM: Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1802-9. doi: 10.1161/ATVBAHA.110.208900. Epub 2010 Jun 3. [PubMed:20522800 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Prostaglandin-i synthase activity
Specific Function:
Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).
Gene Name:
PTGIS
Uniprot ID:
Q16647
Molecular Weight:
57103.385 Da
References
  1. Nakayama T: Genetic polymorphisms of prostacyclin synthase gene and cardiovascular disease. Int Angiol. 2010 Apr;29(2 Suppl):33-42. [PubMed:20357747 ]
  2. Ruan KH, Wu J, Cervantes V: Characterization of the substrate mimic bound to engineered prostacyclin synthase in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of prostacyclin. Biochemistry. 2008 Jan 15;47(2):680-8. Epub 2007 Dec 15. [PubMed:18081314 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:43